P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev
{"title":"在类风湿关节炎患者中使用一种新型白细胞介素-6受体抑制剂来利单抗的实际问题","authors":"P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev","doi":"10.32756/0869-5490-2022-4-40-47","DOIUrl":null,"url":null,"abstract":"Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis\",\"authors\":\"P. Novikov, E. Kuznetsova, N. Nosova, T. Shevtsova, M. Litvinova, V. Logina, S. Moiseev\",\"doi\":\"10.32756/0869-5490-2022-4-40-47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.\",\"PeriodicalId\":10353,\"journal\":{\"name\":\"Clinical pharmacology and therapy\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacology and therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32756/0869-5490-2022-4-40-47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacology and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32756/0869-5490-2022-4-40-47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis
Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR. The authors present two patients with rheumatoid arthritis who were treated successfully with levilimab and discuss various issues of its use in clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
